Waltham, MA J. Calnan & Associates, Inc. (JC&A) has completed a project for Biocytogen Pharmaceuticals. The grand opening of Biocytogen’s new 37,000 s/f facility, marks a notable achievement in advancing research and development in the global biomedical sector.

JC&A has worked alongside LeftField Project Management, Hammel, Green & Abrahamson, and AHA Engineers to bring this project to life. Located at 300 Third Ave., this facility integrates BSL2 lab & vivarium space with sophisticated class A office space, fostering synergy and innovation among researchers and office workers.

The collaboration signifies a significant milestone in the field of biomedical research, propelling Biocytogen Pharmaceuticals as a leader in integrated solutions for next-generation antibody drug development. The facility’s highlights include a climate-controlled 4,000 cage vivarium, advanced cell culture and procedure suites, and an open-concept design that encourages cross-disciplinary collaboration among teams and partners.

This achievement solidifies Biocytogen’s commitment to providing exceptional preclinical contract research services and distributing specialized animal model products (BioMice). These products are increasingly sought after by clients spanning North America and Europe. With an extensive portfolio encompassing over 500 strains of specialized mice, Biocytogen has positioned itself as a global frontrunner in humanized animal models. The facility’s cutting-edge resources, such as the flagship RenMab model and second-generation RenMice-based platforms, empower researchers to explore novel antibody and cell-based therapeutics with diverse applications.

Jeff Cameron, partner and project executive at JC&A, expressed his enthusiasm, said, “The completion of Biocytogen’s new facility is a testament to JC&A’s unwavering commitment to innovation in building within the life sciences sector. Our partnership with Biocytogen highlights our dedication to shaping the future of biomedical research by providing exceptional environments for groundbreaking discoveries.”

Biocytogen is the latest project in a portfolio that features complex projects for clients including Merck & Co, Biogen, Schrodinger, Inc, Lyra Therapeutics, TScan Therapeutics, and Affinia Therapeutics.